Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus

Background Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration of levetiracetam in healthy dogs. The purpose of the present study was to determi...

Full description

Saved in:

Bibliographic Details
Published in:	BMC veterinary research Vol. 14; no. 1; p. 189
Main Authors:	Cagnotti, Giulia, Odore, Rosangela, Gardini, Giulia, Amedeo, Stefano, Bertone, Iride, Guerriero, Giulia, Lentini, Laura, Dappiano, Elena, D’Angelo, Antonio
Format:	Journal Article
Language:	English
Published:	London BioMed Central 18.06.2018 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Administration, Rectal Animals anticonvulsants Anticonvulsants - administration & dosage Anticonvulsants - pharmacokinetics Anticonvulsants - therapeutic use Antiepileptic agents Binding sites blood serum Catheters Chromatography Consciousness Dog Diseases - drug therapy Dogs Dosage and administration Drug dosages Drug therapy Emergency Epilepsy Etiracetam Female Health aspects Levetiracetam Male Medicine Medicine & Public Health Neurology Neurology and neuroscience Patients Pharmacokinetics Pilot Projects Piracetam - administration & dosage Piracetam - analogs & derivatives Piracetam - pharmacokinetics Piracetam - therapeutic use protocols Publishing Rectum Research Article Risk factors Seizures Seizures - drug therapy Seizures - veterinary Status Epilepticus - drug therapy Status Epilepticus - veterinary Transgenics Veterinary medicine Veterinary Medicine/Veterinary Science Zoology United States > US Neurology Emergency Pharmacokinetics Epilepsy
ISSN:	1746-6148, 1746-6148
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Background Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration of levetiracetam in healthy dogs. The purpose of the present study was to determine the pharmacokinetics of rectal LEV in dogs presented for cluster seizures or status epilepticus and potentially in treatment with other anti-epileptic drugs. Furthermore, preliminary information on response to this treatment as add-on to the standard treatment protocol is reported. Results Eight client-owned dogs were enrolled. Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 μg/ml) at 30 min in all but one patient. At T1 (30 min) the mean concentration was 28.2 ± 15.5 μg/ml. Plasma concentrations remained above the targeted minimum concentration in all patients until 240 min and in 7/8 until 360 min. Six out of eight patients experienced no seizures in the 24-h period after hospitalization and were classified as “responders”. Conclusions Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs. These preliminary results may encourage the evaluation of rectal levetiracetam as an additional treatment option for cluster seizures and status epilepticus in a larger number of dogs.
AbstractList	Background Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration of levetiracetam in healthy dogs. The purpose of the present study was to determine the pharmacokinetics of rectal LEV in dogs presented for cluster seizures or status epilepticus and potentially in treatment with other anti-epileptic drugs. Furthermore, preliminary information on response to this treatment as add-on to the standard treatment protocol is reported. Results Eight client-owned dogs were enrolled. Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 [mu]g/ml) at 30 min in all but one patient. At T1 (30 min) the mean concentration was 28.2 [+ or -] 15.5 [mu]g/ml. Plasma concentrations remained above the targeted minimum concentration in all patients until 240 min and in 7/8 until 360 min. Six out of eight patients experienced no seizures in the 24-h period after hospitalization and were classified as "responders". Conclusions Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs. These preliminary results may encourage the evaluation of rectal levetiracetam as an additional treatment option for cluster seizures and status epilepticus in a larger number of dogs. Keywords: Epilepsy, Pharmacokinetics, Neurology, Emergency Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration of levetiracetam in healthy dogs. The purpose of the present study was to determine the pharmacokinetics of rectal LEV in dogs presented for cluster seizures or status epilepticus and potentially in treatment with other anti-epileptic drugs. Furthermore, preliminary information on response to this treatment as add-on to the standard treatment protocol is reported.BACKGROUNDLevetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration of levetiracetam in healthy dogs. The purpose of the present study was to determine the pharmacokinetics of rectal LEV in dogs presented for cluster seizures or status epilepticus and potentially in treatment with other anti-epileptic drugs. Furthermore, preliminary information on response to this treatment as add-on to the standard treatment protocol is reported.Eight client-owned dogs were enrolled. Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 μg/ml) at 30 min in all but one patient. At T1 (30 min) the mean concentration was 28.2 ± 15.5 μg/ml. Plasma concentrations remained above the targeted minimum concentration in all patients until 240 min and in 7/8 until 360 min. Six out of eight patients experienced no seizures in the 24-h period after hospitalization and were classified as "responders".RESULTSEight client-owned dogs were enrolled. Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 μg/ml) at 30 min in all but one patient. At T1 (30 min) the mean concentration was 28.2 ± 15.5 μg/ml. Plasma concentrations remained above the targeted minimum concentration in all patients until 240 min and in 7/8 until 360 min. Six out of eight patients experienced no seizures in the 24-h period after hospitalization and were classified as "responders".Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs. These preliminary results may encourage the evaluation of rectal levetiracetam as an additional treatment option for cluster seizures and status epilepticus in a larger number of dogs.CONCLUSIONSMinimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs. These preliminary results may encourage the evaluation of rectal levetiracetam as an additional treatment option for cluster seizures and status epilepticus in a larger number of dogs. Background Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration of levetiracetam in healthy dogs. The purpose of the present study was to determine the pharmacokinetics of rectal LEV in dogs presented for cluster seizures or status epilepticus and potentially in treatment with other anti-epileptic drugs. Furthermore, preliminary information on response to this treatment as add-on to the standard treatment protocol is reported. Results Eight client-owned dogs were enrolled. Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 μg/ml) at 30 min in all but one patient. At T1 (30 min) the mean concentration was 28.2 ± 15.5 μg/ml. Plasma concentrations remained above the targeted minimum concentration in all patients until 240 min and in 7/8 until 360 min. Six out of eight patients experienced no seizures in the 24-h period after hospitalization and were classified as “responders”. Conclusions Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs. These preliminary results may encourage the evaluation of rectal levetiracetam as an additional treatment option for cluster seizures and status epilepticus in a larger number of dogs. Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration of levetiracetam in healthy dogs. The purpose of the present study was to determine the pharmacokinetics of rectal LEV in dogs presented for cluster seizures or status epilepticus and potentially in treatment with other anti-epileptic drugs. Furthermore, preliminary information on response to this treatment as add-on to the standard treatment protocol is reported. Eight client-owned dogs were enrolled. Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 [mu]g/ml) at 30 min in all but one patient. At T1 (30 min) the mean concentration was 28.2 [+ or -] 15.5 [mu]g/ml. Plasma concentrations remained above the targeted minimum concentration in all patients until 240 min and in 7/8 until 360 min. Six out of eight patients experienced no seizures in the 24-h period after hospitalization and were classified as "responders". Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs. These preliminary results may encourage the evaluation of rectal levetiracetam as an additional treatment option for cluster seizures and status epilepticus in a larger number of dogs. Abstract Background Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration of levetiracetam in healthy dogs. The purpose of the present study was to determine the pharmacokinetics of rectal LEV in dogs presented for cluster seizures or status epilepticus and potentially in treatment with other anti-epileptic drugs. Furthermore, preliminary information on response to this treatment as add-on to the standard treatment protocol is reported. Results Eight client-owned dogs were enrolled. Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 μg/ml) at 30 min in all but one patient. At T1 (30 min) the mean concentration was 28.2 ± 15.5 μg/ml. Plasma concentrations remained above the targeted minimum concentration in all patients until 240 min and in 7/8 until 360 min. Six out of eight patients experienced no seizures in the 24-h period after hospitalization and were classified as “responders”. Conclusions Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs. These preliminary results may encourage the evaluation of rectal levetiracetam as an additional treatment option for cluster seizures and status epilepticus in a larger number of dogs. Background Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration of levetiracetam in healthy dogs. The purpose of the present study was to determine the pharmacokinetics of rectal LEV in dogs presented for cluster seizures or status epilepticus and potentially in treatment with other anti-epileptic drugs. Furthermore, preliminary information on response to this treatment as add-on to the standard treatment protocol is reported. Results Eight client-owned dogs were enrolled. Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 μg/ml) at 30 min in all but one patient. At T1 (30 min) the mean concentration was 28.2 ± 15.5 μg/ml. Plasma concentrations remained above the targeted minimum concentration in all patients until 240 min and in 7/8 until 360 min. Six out of eight patients experienced no seizures in the 24-h period after hospitalization and were classified as “responders”. Conclusions Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs. These preliminary results may encourage the evaluation of rectal levetiracetam as an additional treatment option for cluster seizures and status epilepticus in a larger number of dogs. Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted serum drug concentration after rectal administration of levetiracetam in healthy dogs. The purpose of the present study was to determine the pharmacokinetics of rectal LEV in dogs presented for cluster seizures or status epilepticus and potentially in treatment with other anti-epileptic drugs. Furthermore, preliminary information on response to this treatment as add-on to the standard treatment protocol is reported. Eight client-owned dogs were enrolled. Plasma levetiracetam concentrations (measured at 0, 30, 60, 90, 120, 180, 240, 360, 720, and 1440 min after drug administration) reached the minimum target concentration (5 μg/ml) at 30 min in all but one patient. At T1 (30 min) the mean concentration was 28.2 ± 15.5 μg/ml. Plasma concentrations remained above the targeted minimum concentration in all patients until 240 min and in 7/8 until 360 min. Six out of eight patients experienced no seizures in the 24-h period after hospitalization and were classified as "responders". Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs. These preliminary results may encourage the evaluation of rectal levetiracetam as an additional treatment option for cluster seizures and status epilepticus in a larger number of dogs.
ArticleNumber	189
Audience	Academic
Author	D’Angelo, Antonio Dappiano, Elena Bertone, Iride Lentini, Laura Odore, Rosangela Amedeo, Stefano Guerriero, Giulia Gardini, Giulia Cagnotti, Giulia
Author_xml	– sequence: 1 givenname: Giulia orcidid: 0000-0003-1287-6723 surname: Cagnotti fullname: Cagnotti, Giulia email: giulia.cagnotti@unito.it organization: Department of Veterinary Science, University of Turin – sequence: 2 givenname: Rosangela surname: Odore fullname: Odore, Rosangela organization: Department of Veterinary Science, University of Turin – sequence: 3 givenname: Giulia surname: Gardini fullname: Gardini, Giulia organization: Department of Veterinary Science, University of Turin – sequence: 4 givenname: Stefano surname: Amedeo fullname: Amedeo, Stefano organization: Department of Veterinary Science, University of Turin – sequence: 5 givenname: Iride surname: Bertone fullname: Bertone, Iride organization: Department of Veterinary Science, University of Turin – sequence: 6 givenname: Giulia surname: Guerriero fullname: Guerriero, Giulia organization: Department of Veterinary Science, University of Turin – sequence: 7 givenname: Laura surname: Lentini fullname: Lentini, Laura organization: Department of Veterinary Science, University of Turin – sequence: 8 givenname: Elena surname: Dappiano fullname: Dappiano, Elena organization: Department of Veterinary Science, University of Turin – sequence: 9 givenname: Antonio surname: D’Angelo fullname: D’Angelo, Antonio organization: Department of Veterinary Science, University of Turin
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/29914474$$D View this record in MEDLINE/PubMed
BookMark	eNqNkk1vFSEYhSemxn7oD3BjJnHjZiowwMDGpGn8aNJEF7om78DLLXVmuMJMTf31cr2t7W3UmFlA4JwHOHMOq70pTlhVzyk5plTJ15kyTbuGUNVQwVhDHlUHtOOykZSrvXvz_eow50tCONedfFLtM60p5x0_qL5_uoA0go1fw4RzsLmOvk5oZxjqAa_KUgKLM4w15Bqca-JUzwlhHnGa6zDVLq7KhvfFgq7ur2s7LHnGVGcMP5aEBVjmM8xLrnEdBlyXU5b8tHrsYcj47GY8qr68e_v59ENz_vH92enJeWNlK-cGiAXX-pYI4VQvmQTrBfaSauEkRc85JaynXLTQcQFMciHA9V4j6s5b1h5VZ1uui3Bp1imMkK5NhGB-LcS0MpDKjQY0TlHJqORac8GB8Z51PaiOAyhAr3xhvdmy1ks_orMlgQTDDnR3ZwoXZhWvjCRESt0WwKsbQIrfFsyzGUO2OAwwYVyyYURxIqSk6j-koqOtpC0t0pcPpJdxSVNJdaOSWpUa6DvVCspbw-RjuaLdQM2J4FJ1jDBSVMd_UJXP4RhsaZ8vf3DX8OJ-Jr_DuG1YEXRbgU0x54Te2FDaEOImojAYSsymy2bbZVO6bDZdNhs0feC8hf_Lw7aeXLTTCtNdFn83_QTWGwXJ
CitedBy_id	crossref_primary_10_1002_inpr_370 crossref_primary_10_1111_jvim_15541 crossref_primary_10_1684_epd_2022_1468 crossref_primary_10_1111_jvim_16928
Cites_doi	10.1080/0049825042000196749 10.1111/jvim.12443 10.1073/pnas.0308208101 10.1111/j.1939-1676.2009.0368.x 10.1111/j.1528-1167.2009.02397.x 10.2460/javma.2001.219.618 10.1186/s12917-015-0340-x 10.1111/jvim.12548 10.1111/jvim.12269 10.1136/vr.100316 10.1079/9781780641096.0425 10.1111/j.1528-1167.2008.01889.x 10.1111/j.1528-1167.2008.01561.x 10.1111/epi.12037 10.1111/j.1365-2885.2010.01188.x 10.1111/j.1939-1676.2007.tb03017.x 10.2460/javma.1995.206.11.1721 10.1111/j.1748-5827.2012.01251.x 10.1079/9781780641096.0503 10.1079/9781780641096.0519 10.1111/j.1939-1676.1995.tb03275.x 10.2165/00003088-200443110-00002 10.1371/journal.pone.0106026 10.1186/s12917-015-0461-2
ContentType	Journal Article
Copyright	The Author(s). 2018 COPYRIGHT 2018 BioMed Central Ltd. Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s). 2018 – notice: COPYRIGHT 2018 BioMed Central Ltd. – notice: Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QG 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM DOA
DOI	10.1186/s12917-018-1522-0
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Animal Behavior Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic
DatabaseTitleList	MEDLINE - Academic Publicly Available Content Database AGRICOLA MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Veterinary Medicine Zoology
EISSN	1746-6148
EndPage	189
ExternalDocumentID	oai_doaj_org_article_d816216499454a24b27ba874aa8aef8f PMC6006693 A546872020 29914474 10_1186_s12917_018_1522_0
Genre	Clinical Trial Journal Article
GeographicLocations	United States--US
GeographicLocations_xml	– name: United States--US
GrantInformation_xml	– fundername: Research funded by the University – fundername: ;
GroupedDBID	--- 0R~ 23N 2WC 2XV 53G 5GY 5VS 6J9 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAHBH AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS APEBS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECGQY EJD EMB EMK EMOBN ESX EYRJQ F5P FYUFA GROUPED_DOAJ HMCUK HYE IAG IAO IHR INH INR ITC ITG ITH KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP WOQ WOW XSB AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7QG 7U9 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 7S9 L.6 5PM
ID	FETCH-LOGICAL-c636t-a0cad3f3055d8b626acf5eb6195d61ef44102b1453a745a26455adbf9ee97fc23
IEDL.DBID	RSV
ISICitedReferencesCount	5
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000435579000003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1746-6148
IngestDate	Fri Oct 03 12:50:46 EDT 2025 Tue Nov 04 01:58:12 EST 2025 Sun Nov 09 12:48:25 EST 2025 Thu Oct 02 05:54:56 EDT 2025 Sat Oct 11 05:52:50 EDT 2025 Tue Nov 11 10:17:12 EST 2025 Tue Nov 04 17:41:28 EST 2025 Wed Feb 19 02:42:19 EST 2025 Sat Nov 29 05:25:29 EST 2025 Tue Nov 18 21:40:39 EST 2025 Sat Sep 06 07:25:09 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Neurology Emergency Pharmacokinetics Epilepsy
Language	English
License	Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c636t-a0cad3f3055d8b626acf5eb6195d61ef44102b1453a745a26455adbf9ee97fc23
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23
ORCID	0000-0003-1287-6723
OpenAccessLink	https://link.springer.com/10.1186/s12917-018-1522-0
PMID	29914474
PQID	2056981749
PQPubID	55144
PageCount	1
ParticipantIDs	doaj_primary_oai_doaj_org_article_d816216499454a24b27ba874aa8aef8f pubmedcentral_primary_oai_pubmedcentral_nih_gov_6006693 proquest_miscellaneous_2084056618 proquest_miscellaneous_2057136131 proquest_journals_2056981749 gale_infotracmisc_A546872020 gale_infotracacademiconefile_A546872020 pubmed_primary_29914474 crossref_citationtrail_10_1186_s12917_018_1522_0 crossref_primary_10_1186_s12917_018_1522_0 springer_journals_10_1186_s12917_018_1522_0
PublicationCentury	2000
PublicationDate	2018-06-18
PublicationDateYYYYMMDD	2018-06-18
PublicationDate_xml	– month: 06 year: 2018 text: 2018-06-18 day: 18
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	BMC veterinary research
PublicationTitleAbbrev	BMC Vet Res
PublicationTitleAlternate	BMC Vet Res
PublicationYear	2018
Publisher	BioMed Central BioMed Central Ltd Springer Nature B.V BMC
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC
References	BA Lynch (1522_CR15) 2004; 101 R Zimmermann (1522_CR8) 2009; 23 P Kwan (1522_CR23) 2010; 51 PN Patsalos (1522_CR14) 2004; 43 JWF Uges (1522_CR24) 2009; 50 PN Patsalos (1522_CR19) 2008; 49 RMA Packer (1522_CR6) 2014; 9 1522_CR2 RK Peters (1522_CR17) 2014; 28 1522_CR18 SA Moore (1522_CR22) 2011; 34 N Fredsø (1522_CR7) 2014; 28 TZ Deeb (1522_CR13) 2012; 53 L Arrol (1522_CR4) 2012; 170 M Strolin Benedetti (1522_CR20) 2004; 34 SR Platt (1522_CR11) 2014 M Berendt (1522_CR9) 2007; 21 RMA Packer (1522_CR16) 2015; 11 M Podell (1522_CR10) 1995; 9 KR Muñana (1522_CR21) 2015; 29 M Saito (1522_CR3) 2001; 219 SR Platt (1522_CR12) 2014 M Podell (1522_CR1) 1995; 206 R Monteiro (1522_CR5) 2012; 53 15301575 - Clin Pharmacokinet. 2004;43(11):707-24 25252168 - J Vet Intern Med. 2014 Nov-Dec;28(6):1782-8 23216581 - Epilepsia. 2012 Dec;53 Suppl 9:79-88 17708395 - J Vet Intern Med. 2007 Jul-Aug;21(4):754-9 11549089 - J Am Vet Med Assoc. 2001 Sep 1;219(5):618-23 25153799 - PLoS One. 2014 Aug 25;9(8):e106026 15204700 - Xenobiotica. 2004 Mar;34(3):281-300 18397299 - Epilepsia. 2008 Jul;49(7):1239-76 7760312 - J Vet Intern Med. 1995 Mar-Apr;9(2):68-74 21219341 - J Vet Pharmacol Ther. 2011 Feb;34(1):31-4 19054418 - Epilepsia. 2009 Mar;50(3):415-21 25889090 - BMC Vet Res. 2015 Feb 07;11:25 22835069 - J Small Anim Pract. 2012 Sep;53(9):526-30 26316133 - BMC Vet Res. 2015 Aug 28;11:182 7782244 - J Am Vet Med Assoc. 1995 Jun 1;206(11):1721-8 24417468 - J Vet Intern Med. 2014 Mar-Apr;28(2):504-9 19889013 - Epilepsia. 2010 Jun;51(6):1069-77 22266685 - Vet Rec. 2012 Mar;170(13):335 15210974 - Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6 19737178 - J Vet Intern Med. 2009 Sep-Oct;23(5):970-6 25711374 - J Vet Intern Med. 2015 Mar-Apr;29(2):614-9
References_xml	– volume: 34 start-page: 281 year: 2004 ident: 1522_CR20 publication-title: Xenobiotica doi: 10.1080/0049825042000196749 – volume: 28 start-page: 1782 year: 2014 ident: 1522_CR7 publication-title: J Vet Intern Med doi: 10.1111/jvim.12443 – volume: 101 start-page: 9861 year: 2004 ident: 1522_CR15 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0308208101 – volume: 23 start-page: 970 year: 2009 ident: 1522_CR8 publication-title: J Vet Intern Med doi: 10.1111/j.1939-1676.2009.0368.x – volume: 51 start-page: 1069 year: 2010 ident: 1522_CR23 publication-title: Epilepsia doi: 10.1111/j.1528-1167.2009.02397.x – volume: 219 start-page: 618 year: 2001 ident: 1522_CR3 publication-title: J Am Vet Med Assoc doi: 10.2460/javma.2001.219.618 – volume: 11 start-page: 25 year: 2015 ident: 1522_CR16 publication-title: BMC Vet Res doi: 10.1186/s12917-015-0340-x – volume: 29 start-page: 614 year: 2015 ident: 1522_CR21 publication-title: J Vet Intern Med doi: 10.1111/jvim.12548 – volume: 28 start-page: 504 year: 2014 ident: 1522_CR17 publication-title: J Vet Intern Med doi: 10.1111/jvim.12269 – volume: 170 start-page: 335 year: 2012 ident: 1522_CR4 publication-title: Vet Rec doi: 10.1136/vr.100316 – ident: 1522_CR18 doi: 10.1079/9781780641096.0425 – volume: 50 start-page: 415 year: 2009 ident: 1522_CR24 publication-title: Epilepsia doi: 10.1111/j.1528-1167.2008.01889.x – volume: 49 start-page: 1239 year: 2008 ident: 1522_CR19 publication-title: Epilepsia doi: 10.1111/j.1528-1167.2008.01561.x – volume: 53 start-page: 79 year: 2012 ident: 1522_CR13 publication-title: Epilepsia doi: 10.1111/epi.12037 – volume: 34 start-page: 31 year: 2011 ident: 1522_CR22 publication-title: J Vet Pharmacol Ther doi: 10.1111/j.1365-2885.2010.01188.x – volume: 21 start-page: 754 year: 2007 ident: 1522_CR9 publication-title: J Vet Intern Med doi: 10.1111/j.1939-1676.2007.tb03017.x – volume: 206 start-page: 1721 year: 1995 ident: 1522_CR1 publication-title: J Am Vet Med Assoc doi: 10.2460/javma.1995.206.11.1721 – volume: 53 start-page: 526 year: 2012 ident: 1522_CR5 publication-title: J Small Anim Pract doi: 10.1111/j.1748-5827.2012.01251.x – start-page: 503 volume-title: Canine and feline epilepsy year: 2014 ident: 1522_CR11 doi: 10.1079/9781780641096.0503 – start-page: 519 volume-title: Canine and feline epilepsy year: 2014 ident: 1522_CR12 doi: 10.1079/9781780641096.0519 – volume: 9 start-page: 68 year: 1995 ident: 1522_CR10 publication-title: J Vet Intern Med doi: 10.1111/j.1939-1676.1995.tb03275.x – volume: 43 start-page: 707 year: 2004 ident: 1522_CR14 publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200443110-00002 – volume: 9 start-page: e106026 year: 2014 ident: 1522_CR6 publication-title: PLoS One doi: 10.1371/journal.pone.0106026 – ident: 1522_CR2 doi: 10.1186/s12917-015-0461-2 – reference: 26316133 - BMC Vet Res. 2015 Aug 28;11:182 – reference: 19737178 - J Vet Intern Med. 2009 Sep-Oct;23(5):970-6 – reference: 7760312 - J Vet Intern Med. 1995 Mar-Apr;9(2):68-74 – reference: 22835069 - J Small Anim Pract. 2012 Sep;53(9):526-30 – reference: 21219341 - J Vet Pharmacol Ther. 2011 Feb;34(1):31-4 – reference: 19889013 - Epilepsia. 2010 Jun;51(6):1069-77 – reference: 15210974 - Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9861-6 – reference: 24417468 - J Vet Intern Med. 2014 Mar-Apr;28(2):504-9 – reference: 15301575 - Clin Pharmacokinet. 2004;43(11):707-24 – reference: 25153799 - PLoS One. 2014 Aug 25;9(8):e106026 – reference: 25252168 - J Vet Intern Med. 2014 Nov-Dec;28(6):1782-8 – reference: 22266685 - Vet Rec. 2012 Mar;170(13):335 – reference: 25889090 - BMC Vet Res. 2015 Feb 07;11:25 – reference: 15204700 - Xenobiotica. 2004 Mar;34(3):281-300 – reference: 25711374 - J Vet Intern Med. 2015 Mar-Apr;29(2):614-9 – reference: 18397299 - Epilepsia. 2008 Jul;49(7):1239-76 – reference: 7782244 - J Am Vet Med Assoc. 1995 Jun 1;206(11):1721-8 – reference: 19054418 - Epilepsia. 2009 Mar;50(3):415-21 – reference: 23216581 - Epilepsia. 2012 Dec;53 Suppl 9:79-88 – reference: 11549089 - J Am Vet Med Assoc. 2001 Sep 1;219(5):618-23 – reference: 17708395 - J Vet Intern Med. 2007 Jul-Aug;21(4):754-9
SSID	ssj0044976
Score	2.1574683
Snippet	Background Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum... Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum targeted... Background Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum... BACKGROUND: Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the minimum... Abstract Background Levetiracetam can be used for seizure control alone or in combination with other antiepileptic medications. A previous study achieved the...
SourceID	doaj pubmedcentral proquest gale pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	189
SubjectTerms	Administration, Rectal Animals anticonvulsants Anticonvulsants - administration & dosage Anticonvulsants - pharmacokinetics Anticonvulsants - therapeutic use Antiepileptic agents Binding sites blood serum Catheters Chromatography Consciousness Dog Diseases - drug therapy Dogs Dosage and administration Drug dosages Drug therapy Emergency Epilepsy Etiracetam Female Health aspects Levetiracetam Male Medicine Medicine & Public Health Neurology Neurology and neuroscience Patients Pharmacokinetics Pilot Projects Piracetam - administration & dosage Piracetam - analogs & derivatives Piracetam - pharmacokinetics Piracetam - therapeutic use protocols Publishing Rectum Research Article Risk factors Seizures Seizures - drug therapy Seizures - veterinary Status Epilepticus - drug therapy Status Epilepticus - veterinary Transgenics Veterinary medicine Veterinary Medicine/Veterinary Science Zoology
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQxYELgvIKFGQkJCRQ1CS2Y_tYEBUXqh4A9Wb5FVixTVab3SL49cw42dAUUS7cEnssOfZ45ht58g0hL6KSgUEsnTte2Jw7UeWu1iKXLCoWwSoXgadiE_LkRJ2d6dNLpb4wJ2ygBx4W7jCosq4A02vNBbcVd5V0VklurbKxUQ1a30LqXTA12GDOwcuOd5ilqg978GolplhCxASAIy9mXiiR9f9pki_5pKv5klcuTZMvOr5Dbo8gkh4Nk79LbsR2n-x_xsyW9Hst_TDemN8j309Hbupv8IqUzLRrKFo5GL-MF9C0tj5u7Dm1PQUrlHctnZLP6aKlofsCHSnrIwbqflC_3CK5Au3j4ucWgnXawTNA1m1P4wpszArpPPr75NPxu49v3-djsYXc16ze5LbwNrAGCcCCchDmWN-I6CC-EqEuYwOwqahcyQWzkgsLOEoIG1yjY9Sy8RV7QPbaro2PCI2hgOYKCZ0sL3x0UgVtvWBRgi64MiPFbvGNH5nIsSDG0qSIRNVm2C8D-2Vwv0yRkVfTkNVAw3Gd8Bvc0UkQGbRTA-iVGfXK_EuvMvIS9cHgOYfJeTv-rgCfiIxZ5kjwWskK0HZGDmaScD79vHunUWa0D72pAHdqBdGgzsjzqRtHYs5bG7ttkpElA7hVXicDATog8lJl5OGgpNNnA9CAaFnyjMiZ-s7WZd7TLr4mhvEakahmGXm9U_TfU__rsj_-H8v-hNyq8JhidSh1QPY26218Sm76i82iXz9Lh_wX6HZV_g priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagcODCo7wCBRkJCQkUkYcdOydUEBUXqh4A7c3yK-2KJVk2myL49cx4vSkpYi_cEj-kOB6Pvy-efEPIcy-FK4FLp4ZlOmWGF6mpap6K0svSg1fOHAvJJsTxsZzN6pP4wa2PYZVbnxgctessfiMHks6rWgJ-rt8sv6eYNQpPV2MKjavkGqbNRjsXs5FwMQZ7bTzJzGX1uoe9LcdAS-BNADvSbLIXBcn-vx3zHzvT5ajJS0enYUc6uvW_Y7lNbkYsSg83xnOHXPHtPtn_ggEy4S9d-jEevN8lP06ixPVXuEVlZ9o1FJ0l9F_4cyhaaevX-hvVPQVnlnYtHWPY6bylrjuFihA84h01P6ldDKjRQHs__zUA56cdXAPyHXrql-CqlqgK0t8jn4_ef3r3IY05G1JbldU61ZnVrmxQR8xJA2xJ24Z7AzSNuyr3DaCvrDA546UWjGuAY5xrZ5ra-1o0tijvk722a_1DQr3LoLhAXSjNMuuNkK7WlpdegEmZPCHZdvaUjYLmmFdjoQKxkZXaTLiCCVc44SpLyMuxy3Kj5rGr8Vs0ibEhCnGHgm51quK6Vk7mVQGUs64ZZ7pgphBGS8G0lto3sknICzQohe4CHs7q-NcDDBGFt9QhZ5UUBYD2hBxMWsIyt9PqrS2p6GZ6dWFICXk2VmNPDJ1rfTeENiIvAbXlu9oAzwdgn8uEPNhY-ThswCtAugVLiJjY_-S9TGva-VkQKq8Q0NZlQl5tV8rFo__ztT_aPdDH5EaBKxjTR8kDsrdeDf4JuW7P1_N-9TSs_9-SJmRM priority: 102 providerName: ProQuest
Title	Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus
URI	https://link.springer.com/article/10.1186/s12917-018-1522-0 https://www.ncbi.nlm.nih.gov/pubmed/29914474 https://www.proquest.com/docview/2056981749 https://www.proquest.com/docview/2057136131 https://www.proquest.com/docview/2084056618 https://pubmed.ncbi.nlm.nih.gov/PMC6006693 https://doaj.org/article/d816216499454a24b27ba874aa8aef8f
Volume	14
WOSCitedRecordID	wos000435579000003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1746-6148 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0044976 issn: 1746-6148 databaseCode: RBZ dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1746-6148 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0044976 issn: 1746-6148 databaseCode: DOA dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1746-6148 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0044976 issn: 1746-6148 databaseCode: M~E dateStart: 20050101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1746-6148 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0044976 issn: 1746-6148 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1746-6148 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0044976 issn: 1746-6148 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1746-6148 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0044976 issn: 1746-6148 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1746-6148 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0044976 issn: 1746-6148 databaseCode: RSV dateStart: 20051201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFD6CDRAvXMotMCojISGBouXixM7jhjbBw6pqwFR4sXzLqChJ1bRD8Os5dpOODJgEL1Vrn0Sxe25ffPwZ4LnlzKSIpUNFIxlSlSWhyossZKnlqUWvHBnqD5tgoxGfTIpxu4-76arduyVJ76m9WfN8t8HIFLsySUQ9mDSEiNO3Mdpxd17D8buTzv1SigG2Xb7842W9AOR5-n_3xr-Eo4ulkhfWS30YOrz9XwO4A7farJPsrdXkLlyx1QBuHLXr6gMYnLiqGL81l5y3Xv9U-5fu9-DbuGW4_oIdjtiZ1CVxvhJvOrNn2LSQ2i7lVyIbgr4srCuyKWEn04qY-hQ7fO2INUR9J3q2chQNpLHTHyuE_KTG75j4rhpi5-ip5o4UpLkPHw4P3r9-E7ZHNoQ6T_NlKCMtTVo6GjHDFYIlqcvMKkRpmcljW2LyFSUqplkqGc0kZmNZJo0qC2sLVuokfQBbVV3ZR0CsibA5cbRQkkbaKsZNIXWWWoYapeIAou5_FLrlM3fHasyExzU8F-sJFzjhwk24iAJ4ublkvibzuEx43ynHRtDxcPuGenEqWrMWhsd5goizKGhGZUJVwpTkjErJpS15GcALp1rCeQt8OC3bTQ84RMe7JfYymnOWYM4ewE5PEq1c97s75RStl2lEgtlrwRFTFgE823S7K13lXGXrlZdhcYpJW3yZDMJ8zOtjHsDDtb5vho3pCmJuRgNgPUvozUu_p5p-9jzluctnizSAV509nD_6X6f98T9JP4GbiTMod5gU34Gt5WJln8I1fbacNoshXGUT5j_5ELb3D0bj46F_6YK_xm-Pxh-H3nX8BAWeZgs
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF5VBQkuPMrLUGCRQEggCz92vesDQuVRtWob9VBQb9t9uUQEO8RJq_Kj-I3MOHaKi8itB27JPiLvZuabGe_sN4Q891K4FGLp0LBIh8zwJDRZzkORepl6QOXIsabYhBgM5OFhvr9CfnV3YTCtssPEBqhdZfEdOQTpPMsl-M_5u_GPEKtG4elqV0JjLhY7_uwUQrb67fZH-H9fJMnmp4MPW2FbVSC0WZpNQx1Z7dICma6cNODPa1twbyCQ4C6LfQH-QZSYmPFUC8Y1OAyca2eK3PtcFBaJDgDyrwCOCwz2xOEiwGMMbHt7chrL7E0NtjTGxE6I08DNCaOe7WtKBPxtCP6whBezNC8c1TYWcPPm_7Z3t8iN1temG3PluE1WfLlG1r5gAlBzC5nutYkFd8jpfkvh_Q2-InM1rQqKxgDmj_wJNE209VP9neqaAliHVUkXOfp0WFJXHUNHkxzjHTVn1I5myEFBaz_8OZt4-EH4DJ79rKZ-DFA8RtaT-i75fCk7cI-sllXpHxDqXQTNCfJeaRZZb4R0ubY89QJUxsQBiTppUbYlbMe6ISPVBG4yU3MBUyBgCgVMRQF5tZgynrOVLBv8HkVwMRCJxpuGanKsWtxSTsZZAiF1njPOdMJMIoyWgmkttS9kEZCXKMAK4RAezur2VgcsEYnF1AZnmRQJBCUBWe-NBBiz_e5OdlULo7U6F9yAPFt040xMDSx9NWvGiDgFrzReNkZCYAKuqAzI_blWLZYN_ljMmGABET196-1Lv6ccfm2I2DN02PM0IK87zTx_9H9u-8PlC31Krm0d7O2q3e3BziNyPUH0wFJZcp2sTicz_5hctSfTYT150mAPJUeXrbC_Ac7ewfM
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELZQgYoXjuUKFDASEhIoag47dh7LsQIBq5WAquLF8pWy6jZZbXaL4Nczk2NLClRCvK3scRTPzoy_icefCXnipXAp5NKhYZEOmeFJaLKchyL1MvUQlSPHmssmxGQiDw7yaXfPad1Xu_dbku2ZBmRpKle7C1e0Li6z3RpWqRhLJiEDAgARQs5-kWEdPabrH_f7UMwYLLbdVuYfhw0Wo4az__fI_MvSdLZs8szeabMkja_992Suk6sdGqV7rfncIBd8OSLbH7r99hEZ7WO1THNkl562Xv5SNR_jb5Jv0475-gg6kPCZVgXFGAoPnfsTaFpq61f6mOqaQowLq5JuStvprKSuOoSOpqbEO2q-UztfI3UDrf3sx3rp4YHwGwDxuqZ-ARFsgWQh9S3yefz608s3YXeVQ2izNFuFOrLapQXSizlpIInStuDeQPbGXRb7AkBZlJiY8VQLxjWgNM61M0XufS4Km6S3yVZZlf4uod5F0JwgXZRmkfVGSJdry1MvwNJMHJCo_0-V7XjO8bqNuWryHZmpVuEKFK5Q4SoKyLPNkEVL8nGe8As0lI0g8nM3DdXyUHXurpyMswQy0TxnnOmEmUQYLQXTWmpfyCIgT9HMFEYReDmru8MQMEXk41J7nGVSJIDlA7IzkATvt8Pu3lBVF31qlQCqzSXkmnlAHm-6cSRW1JW-WjcyIk4BzMXnyUD6D3g_lgG509r-ZtoAYyAXFywgYuAVA70Me8rZ14a_PEOcm6cBed77xumr_1Xt9_5J-hHZnr4aq_dvJ-_ukysJ-hbeNyV3yNZqufYPyCV7sprVy4dNvPgJD_xrww
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+rectal+levetiracetam+as+add-on+treatment+in+dogs+affected+by+cluster+seizures+or+status+epilepticus&rft.jtitle=BMC+veterinary+research&rft.au=Cagnotti%2C+Giulia&rft.au=Odore%2C+Rosangela&rft.au=Gardini%2C+Giulia&rft.au=Amedeo%2C+Stefano&rft.date=2018-06-18&rft.pub=BioMed+Central&rft.eissn=1746-6148&rft.volume=14&rft_id=info:doi/10.1186%2Fs12917-018-1522-0&rft_id=info%3Apmid%2F29914474&rft.externalDocID=PMC6006693
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1746-6148&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1746-6148&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1746-6148&client=summon